Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMMIT: Fluticasone Furoate/Vilanterol Survival Study in Moderate COPD
NCT01313676Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2011
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 44
01
Overview
A Phase 3 trial of fluticasone furoate + vilanterol in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Jan 2011; status: completed.
02
Drugs
fluticasone furoate + vilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01313676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313676.